JAGUAR HEALTH, INC. Long-Term Debt, Maturity, Remainder of Fiscal Year
JAGUAR HEALTH, INC. (JAGX) had Long-Term Debt, Maturity, Remainder of Fiscal Year of $1.54 million as of 2017-03-31, per its 10-Q/A filed 2017-06-23.
Discontinued › Notes › Commitment and Contingencies
us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear · last filed 2017-06-23
- 2017-03-31: Long-Term Debt, Maturity, Remainder of Fiscal Year $1.54M.
- 2016-09-30: Long-Term Debt, Maturity, Remainder of Fiscal Year $477.29K.
- 2016-06-30: Long-Term Debt, Maturity, Remainder of Fiscal Year $633.00K.
- 2016-03-31: Long-Term Debt, Maturity, Remainder of Fiscal Year $1.65M.
| Period end | Long-Term Debt, Maturity, Remainder of Fiscal Year |
|---|---|
| 2017-03-31 | $1.54M 10-Q/A · filed 2017-06-23 |
| 2016-09-30 | $477.29K 10-Q · filed 2016-11-14 |
| 2016-06-30 | $633.00K 10-Q · filed 2016-08-15 |
| 2016-03-31 | $1.65M 10-Q · filed 2016-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |